轻度奥密克戎感染患者接种疫苗与持续性新冠相关症状之间的关联：一项前瞻性队列研究。
Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study.
作者信息
Rover Marciane Maria, Scolari Fernando Luis, Trott Geraldine, da Silva Mariana Motta Dias, de Souza Denise, da Rosa Minho Dos Santos Rosa, De Carli Schardosim Raíne Fogliati, de Souza Roldão Emelyn, Pozza Estivalete Gabriel, Rech Gabriela Soares, Mocellin Duane, de Souza Jennifer Menna Barreto, Miozzo Aline Paula, Itaqui Carolina Rothmann, da Silva Gabrielle Nunes, de Mesquita Neto Juliana, Freitas Hellen Jordan Martins, Dos Santos Catherine Vitória Pereira, da Silveira Alanys Santos, D'Ávila Carla Moura, Soares Christian Morais, Vítor Gozzi João, Dos Santos Ingrid Flor, Carvalho Sidiclei Machado, Irineu Vivian Menezes, Silvestre Odilson Marcos, do Carmo Marinho Borges Kênia, de Menezes Neves Precil Diego Miranda, Junior Fernando Azevedo Medrado, Schleder Juliana Carvalho, Dos Santos Thiago Pelissari, Lanna Figueiredo Estêvão, da Fonseca Benedito Antonio Lopes, Zimmermann Sérgio Luiz, Pompilho Mauricio Antonio, Facchi Luciane Maria, Gebara Otavio Celso Eluf, Marcolino Milena Soriano, Antonio Ana Carolina Peçanha, Schvartzman Paulo R, Barreto Bruna Brandao, Robinson Caroline Cabral, Falavigna Maicon, Nasi Luiz Antônio, Polanczyk Carisi Anne, Biolo Andreia, Rosa Regis Goulart
机构信息
Escritório de Projetos, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.
Serviço de Cardiologia, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.
出版信息
Vaccine X. 2024 Nov 4;21:100579. doi: 10.1016/j.jvacx.2024.100579. eCollection 2024 Dec.
BACKGROUND
While COVID-19 vaccination has been shown to reduce the risk of severe illness, its impact on the occurrence of persistent symptoms in patients with mild Omicron infection remains uncertain. Our objective was to investigate whether COVID-19 vaccination reduces the occurrence of persistent COVID-19-related symptoms 3 months after mild Omicron infection.
METHODS
Multicenter prospective cohort study was conducted in Brazil between January 2022 and June 2023 when Omicron was predominant. Participants ≥ 18 years seeking outpatient care for symptomatic SARS-CoV-2 infection were enrolled. Complete vaccination included individuals who received the full primary series and any booster dose, while incomplete vaccination included those with incomplete primary series or no vaccination. The primary outcome was any persistent symptoms at 3 months. Secondary outcomes were organ system-specific persistent symptoms and the EQ-5D-3L utility score. All outcomes were assessed by means of structured telephone interviews 3 months after enrollment.
RESULTS
1,067 patients were enrolled (median age, 39 years), of which 914 (871 completely vaccinated and 43 unvaccinated or incompletely vaccinated). Among the vaccinated participants the median time since the last vaccine dose was 145 (interquartile range, 106-251) days. A total of 388/1067 (36.9 %) had a prior infection at the time of study entry The occurrence of overall persistent COVID-19-related symptoms at 3 months was 41.6 % (n = 362) among completely vaccinated and 44.2 % (n = 19) among unvaccinated or incompletely vaccinated patients (adjusted risk ratio [aRR], 0.87; 95 % confidence interval [CI], 0.61-1.23; = 0.43). Complete vaccination was associated with lower occurrence of mental health symptoms (aRR, 0.44; 95 % CI, 0.24-0.81; = 0.01). No differences were found in the occurrence of persistent symptoms in other specific domains, nor in EQ-5D-3L utility scores.
CONCLUSIONS
This study was not able to identify a statistically significant protection of complete COVID-19 vaccination against any overall persistent symptoms at 3 months. Nevertheless, complete vaccination was associated with a lower occurrence of persistent mental health symptoms.
背景
虽然新冠病毒疫苗接种已被证明可降低重症风险，但其对轻症奥密克戎感染者持续症状发生情况的影响仍不确定。我们的目的是调查新冠病毒疫苗接种是否能降低轻症奥密克戎感染3个月后新冠病毒相关持续症状的发生率。
方法
于2022年1月至2023年6月在巴西进行了一项多中心前瞻性队列研究，当时奥密克戎毒株占主导。纳入年龄≥18岁、因有症状的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染寻求门诊治疗的参与者。全程接种包括接受完整基础免疫系列和任何加强剂量的个体，而未完成接种包括基础免疫系列不完整或未接种的个体。主要结局是3个月时的任何持续症状。次要结局是特定器官系统的持续症状和欧洲五维度健康量表（EQ-5D-3L）效用评分。所有结局均在入组3个月后通过结构化电话访谈进行评估。
结果
共纳入1067例患者（中位年龄39岁），其中914例（871例全程接种，43例未接种或未完成接种）。在接种疫苗的参与者中，自最后一剂疫苗接种后的中位时间为145天（四分位间距，106-251天）。共有388/1067例（36.9%）在研究入组时曾有过感染。3个月时，全程接种者中新冠病毒相关总体持续症状的发生率为41.6%（n = 362），未接种或未完成接种者中为44.2%（n = 19）（调整风险比[aRR]，0.87；95%置信区间[CI]，0.61-1.23；P = 0.43）。全程接种与心理健康症状发生率较低相关（aRR，0.44；95%CI，0.24-0.81；P = 0.01）。在其他特定领域的持续症状发生率以及EQ-5D-3L效用评分方面未发现差异。
结论
本研究未能确定新冠病毒全程接种在3个月时对任何总体持续症状有统计学意义的保护作用。尽管如此，全程接种与持续心理健康症状发生率较低相关。
Zotero 插件